#Challenges in US Acute Myeloid Leukemia Market | Explore Tumblr Posts and Blogs

kenresearch1 · 7 months

Text

The Transformative Growth of the US Acute Myeloid Leukemia Market

Buy Now

What is the Size of US Acute Myeloid Leukemia Industry?

US Acute Myeloid Leukemia Market is expected to grow at a CAGR of ~ % in 2022 and is expected to reach ~USD Mn by 2028. The US Acute Myeloid Leukemia market is the rapid advancement in precision medicine and targeted therapies. The emergence of innovative treatments tailored to the genetic and molecular characteristics of individual AML patients has transformed the treatment landscape. Targeted therapies, such as FLT3 and IDH inhibitors, capitalize on specific genetic mutations driving AML, resulting in higher response rates and improved outcomes compared to traditional approaches.

Precision medicine's ability to identify the most effective treatment for each patient not only enhances therapeutic efficacy but also reduces unnecessary treatments, mitigating side effects and improving overall quality of life. This paradigm shift is bolstered by technological progress in molecular profiling techniques like next-generation sequencing, allowing for accurate genetic profiling and treatment customization.

Furthermore, regulatory support and accelerated approval pathways for targeted therapies have expedited their availability to patients. Pharmaceutical companies' increasing investment in research and development of novel agents, along with collaborations between academia and industry, leads to grow this market even more.

Click here to Download a Sample Report

US Acute Myeloid Leukemia Market by treatment type

The market is segmented by Treatment type into Chemotherapy, Targeted Therapy, Hormone Therapy, Immunotherapy and Others. Targeted Therapy is the dominant segment in the US Acute Myeloid Leukemia market in 2022. Specialty Centers, dedicated to the diagnosis, treatment, and management of specific medical conditions like AML, offer a concentrated and specialized approach to patient care. Their dominance in the AML market is driven by their unique capabilities to provide comprehensive and tailored treatments that address the complex needs of AML patients.

US Acute Myeloid Leukemia Market by end -user industry

The market is segmented by End-User into Hospitals, Homecare, Specialty Centers, Pharmacies and Others. Among these, Specialty Centers are the dominant End-User in the US Acute Myeloid Leukemia market in 2022. Specialty centers have a higher level of expertise and experience in treating specific types of cancer, including acute leukemia. They typically have specialized medical professionals, including hematologists and oncologists, who are well-versed in the latest treatment protocols and research. These centers are equipped with state-of-the-art diagnostic and treatment facilities that are specifically tailored to the needs of leukemia patients. This can include advanced imaging technologies, specialized laboratories, and access to cutting-edge therapies.

Click here to Download a Custom Report

US Acute Myeloid Leukemia companies market by Region

The US Acute Myeloid Leukemia market is segmented by Region into North, South, East, West. The dominance region is North in the US Acute Myeloid Leukemia Market in 2022. the North region often benefits from a higher level of funding for medical research, including AML. Federal funding agencies, private foundations, and pharmaceutical companies frequently channel resources into institutions within this region, allowing for greater research capabilities and clinical trials infrastructure.

Competition Scenario in US Acute Myeloid Leukemia Market

The US acute myeloid leukemia market was characterized by the presence of several prominent pharmaceutical companies and biotechnology firms striving to establish their presence and gain a competitive edge.

Larger corporations, smaller biotechnology companies making significant contributions to the AML landscape. Companies like Agios Pharmaceuticals and Daiichi Sankyo were gaining attention for their novel therapies targeting AML-associated mutations. These players are often at the forefront of introducing precision medicine approaches to AML treatment, taking advantage of advancements in genetic profiling and molecular diagnostics.

The competition is further intensified by research collaborations and partnerships between pharmaceutical companies, academic institutions, and research organizations. These collaborations aimed to combine resources, expertise, and insights to accelerate the development of effective therapies.

What is the Expected Future Outlook for the Overall US Acute Myeloid Leukemia market?

The US Acute Myeloid Leukemia market was valued at USD ~Million in 2022 and is anticipated to reach USD ~ Million by the end of 2028, witnessing a CAGR of ~% during the forecast period 2022- 2028. Pharmaceutical companies have been actively researching and developing novel therapies for Acute Myeloid Leukemia, with a focus on improving patient outcomes and reducing the side effects associated with traditional treatments like chemotherapy. The approval of new drugs, such as FLT3 and IDH inhibitors, has offered fresh therapeutic avenues for specific subsets of Acute Myeloid Leukemia patients with genetic mutations.

The future outlook for the US Acute Myeloid Leukemia market is anticipated to be influenced by a combination of factors including advancements in treatment options, evolving regulatory landscapes, and a growing understanding of the molecular basis of Acute Myeloid Leukemia. The market has been witnessing a shift towards personalized medicine, with increasing emphasis on targeted therapies and precision medicine approaches.

Furthermore, the integration of innovative technologies like next-generation sequencing (NGS) has enhanced our understanding of Acute Myeloid Leukemia’s molecular complexities, allowing for better patient stratification and treatment selection. This trend toward molecular profiling and personalized treatment regimens is likely to continue shaping the market landscape.

However, challenges persist. Despite progress, Acute Myeloid Leukemia remains a difficult-to-treat disease with a high relapse rate. Overcoming drug resistance and developing effective strategies for patients who do not respond well to existing therapies remain critical areas of focus.

Additionally, the cost of novel therapies and access to these treatments could also impact their adoption and availability. The regulatory environment, including expedited pathways for drug approvals, continue to influence market dynamics.

0 notes

techsciresearch · 3 years

Text

Saudi Arabia Poultry Market to Witness Steady Growth till 2026 | TechSci Research

Strong economic growth and the growing food requirements is expected to drive the demand for Saudi Arabia Poultry market in the forecast period.

According to TechSci Research report, “Saudi Arabia Poultry Market By Type (Broiler, Eggs, Others) By Product Type (Raw, Chilled, Frozen) By Nature (Organic, Conventional) By Distribution Channel (Supermarkets/Hypermarkets, Traditional Stores, Specialized Stores, Online, Others), By region, Company Forecast & Opportunities, 2026”, The Saudi Arabia Poultry market is expected to witness steady growth in the forecast period. The rapid urbanization of the people to live in better conditions and search for employment opportunities is contributing to the growth of the poultry market and enhancing the demand for processed and unprocessed chicken and eggs.

Support of the leading authorities for the development of the poultry market in form of relaxation in income tax, direct subsidies for select food items, interest-free loans, and duty-free imports of raw materials. The leading authorities are providing support to the local manufacturers and taking significant measures to reduce the mortality rate of the bird. An increase in the preference of the consumers for low-fat and high-protein-containing food items is fostering the growing demand of the market. The development of the trade channel and the technological advancements to keep the freshness of the food items and aid in increasing the shelf life of the edible animal food items is fostering the growth of the poultry market.

The increase in the demand for frozen and chilled food items is influencing the demand for poultry-based products in the region. The high demand for the consumption of poultry-based products and the unavailability of quality animal-based edible items in the country and the need to import the animal-based food items are creating lucrative opportunities for the growth of the poultry market. The Saudi government is making heavy investments for the infrastructural development of the country in order to develop the retail and hospitality sector in the country. Under the Saudi Vision 2030, the development of the tourism industry to attract more tourists to the country for religious and other purposes, the government is aiming to develop the poultry sector to meet the growing food requirements.

The COVID-19 outbreak across the world which has been declared as a pandemic by World Health Organization has affected several countries adversely. Leading authorities of Saudi Arabia imposed lockdown restrictions and released a set of precautionary measures to contain the spread of novel coronavirus. The coronavirus pandemic hit the economic status of the country which negatively impacted the growth of the industry. Disruption in the supply chain was observed which adversely affected the supply of raw materials around the country.

However, the growing cost of the poultry feeds and strict quality checks and norms may hamper the Saudi Arabia Poultry market growth in the forecast period.

Browse XX Figures spread through XX Pages and an in-depth TOC on "Saudi Arabia Poultry Market”.

https://www.techsciresearch.com/report/saudi-arabia-poultry-market/7726.html

Saudi Arabia Poultry market is segmented into type, product type, nature, distribution channel, regional distribution, and company. Based on the type, the market can be divided into broiler, eggs, and others. The broiler segment is expected to witness growth in the next five years, 2022-2026. The rise in the demand for whole chicken and its parts and the increasing affordability of the consumers is fostering the growth of this segment. The Hajj pilgrimage attracts a lot of tourists in the country which is expected to fuel the demand and rapid development of the catering service market. The rise in the development of the construction industry and the liability of the company to provide three meals a day is contributing to the growth of the poultry market as the normal diet in Saudi Arabia includes the portion of animal meat or products.

Almarai Saudi Arabia, Al-Watania Poultry Company, Al-Fakeih Poultry, Al-Berri United Food Co. Ltd, Alwadi Poultry Farms Ltd, Co., Arabian Agricultural Services Company, Arabian Farms Dev.Co.Ltd., Alsalamah Almotatawera Co, BRF S.A, Bayle S.A., Cargill Incorporated, Cherkizovo Group are the leading players operating in Saudi Arabia Poultry market. Manufacturers are increasingly focusing on research and development process to fuel higher growth in the market. To meet evolving customer demand with respect to better efficiency and durability, several Poultry manufacturers are coming up with their technologically advanced offerings.

Download Sample Report @ https://www.techsciresearch.com/sample-report.aspx?cid=7726

Customers can also request for 10% free customization on this report.

“Development of the online commerce channels to improve the reach of products and brand image, the market players are investing huge amounts. The offering of attractive discounts and the facility for home delivery and online payment gateways ate contributing to the growth of the market. The market players are adopting advanced technologies such as 3-D imaging systems to determine the way for optimal cuts and minimize the per-unit cost for poultry processing. The use of latest technologies and the development of efficient distribution channels is expected to propel the growth of the Poultry market till 2026” said Mr. Karan Chechi, Research Director with TechSci Research, a global research-based management consulting firm.

“Saudi Arabia Poultry Market By Type (Broiler, Eggs, Others) By Product Type (Raw, Chilled, Frozen) By Nature (Organic, Conventional) By Distribution Channel (Supermarkets/Hypermarkets, Traditional Stores, Specialized Stores, Online, Others), By region, Company Forecast & Opportunities, 2026” has evaluated the future growth potential of Saudi Arabia Poultry market and provided statistics & information on market size, shares, structure and future market growth. The report intends to provide cutting-edge market intelligence and help decision makers take sound investment decisions. Besides, the report also identifies and analyzes the emerging trends along with essential drivers, challenges, and opportunities in the of Saudi Arabia Poultry market.

Browse Related Reports:

Global Organic Food Market By Product Type (Organic Meat, Poultry & Dairy; Organic Fruits & Vegetables; Organic Processed Food; Organic Bread & Bakery; Organic Beverages; Organic Processed Food and Others), By Distribution Channel Type (Hypermarket/Supermarket, Speciality Stores, Departmental Stores, Online and Others (Spices, Pulses, Cereals &Food Grains etc.), By Region, Competition, Forecast Opportunities, 2026

https://www.techsciresearch.com/report/organic-food-market/4401.html

Vietnam Frozen Food Market By Category, ((Ready-to-Eat, Ready-to-Cook & Others (Raw Meat, Raw Vegetables, Raw Fruit, etc.)), By Product Type (Frozen Meat, Poultry, & Seafood, Frozen Snacks, Frozen Fruits & Vegetables, Frozen Desserts, Frozen Cooked Ready Meals, & Others), By Distribution Channel (Departmental Stores, Specialty Stores, Supermarket/Hypermarket, Online & Others (Convenience Stores, Direct Sales, etc.)), By Region, Competition, Forecast Opportunities, 2026F

https://www.techsciresearch.com/report/vietnam-frozen-food-market/2942.html

Global Leukemia Therapeutics Market By Type (Chronic Lymphocytic Leukemia, Acute Myeloid Leukemia, Chronic Myeloid Leukemia, Acute Lymphocytic Leukemia, Others), By Gender (Male, Female), By Age Groups (0-15, 15-30, 30-50, 50+), By Diagnosis (Blood Test, Biopsy, Physical Exam, Imaging), By Treatment (Chemotherapy, Stem Cell Transplantation, Immunotherapy, Targeted Therapy, Others), By Drugs (Tyrosine Kinase Inhibitors, Antimetabolites, Hormones (Corticosteroids), Monoclonal Antibodies, Others), By Route of Administration (Oral, Parenteral), By Region, Competition Forecast & Opportunities, 2026

https://www.techsciresearch.com/report/leukemia-therapeutics-market/4534.html

Global Outpatient Hospital Services Market By Services (Treatment Services, Diagnostic Tests, Minor Surgical Procedures, Others) By Type (Emergency Department, Urgent Care Centers, Primary Care Clinics, Specialized Outpatient Clinics, Others) By Region, Competition Forecast & Opportunities, 2026

https://www.techsciresearch.com/report/outpatient-hospital-services-market/7732.html

Saudi Arabia Seafood Market By Product (Fish, Shrimp, Crab, Lobster, Others) By Type (Raw, Frozen, Processed) By Application (Retail, Institution Sales and Food Service) By Distribution Channel (Supermarket/Hypermarket, Departmental Stores, Specialized Stores, Online, Others), Company Forecast & Opportunities, 2026

https://www.techsciresearch.com/report/saudi-arabia-seafood-market/7727.html

Contact

Mr. Ken Mathews

708 Third Avenue,

Manhattan, NY,

New York – 10017

Tel: +1-646-360-1656

Email: [email protected]

Website: https://www.techsciresearch.com/

For More Market Research Blogs Visit: https://techsciblog.com/

#TechSci #Market Research Reports #Saudi Arabia Poultry Market #Poultry Market #Saudi Arabia Poultry Market Size #Saudi Arabia Poultry Market Forecast

0 notes

techscimarketresearch · 3 years

Text

Saudi Arabia Poultry Market to Witness Steady Growth till 2026 | TechSci Research

Strong economic growth and the growing food requirements is expected to drive the demand for Saudi Arabia Poultry market in the forecast period.

However, the growing cost of the poultry feeds and strict quality checks and norms may hamper the Saudi Arabia Poultry market growth in the forecast period.

Browse XX Figures spread through XX Pages and an in-depth TOC on "Saudi Arabia Poultry Market”.

https://www.techsciresearch.com/report/saudi-arabia-poultry-market/7726.html

Download Sample Report @ https://www.techsciresearch.com/sample-report.aspx?cid=7726

Customers can also request for 10% free customization on this report.

Browse Related Reports:

https://www.techsciresearch.com/report/organic-food-market/4401.html

https://www.techsciresearch.com/report/vietnam-frozen-food-market/2942.html

https://www.techsciresearch.com/report/leukemia-therapeutics-market/4534.html

https://www.techsciresearch.com/report/outpatient-hospital-services-market/7732.html

https://www.techsciresearch.com/report/saudi-arabia-seafood-market/7727.html

Contact

Mr. Ken Mathews

708 Third Avenue,

Manhattan, NY,

New York – 10017

Tel: +1-646-360-1656

Email: [email protected]

Website: https://www.techsciresearch.com/

For More Market Research Blogs Visit: https://techsciblog.com/

#TechSci #Market Research Reports #Saudi Arabia Poultry Market #Poultry Market #Saudi Arabia Poultry Market Size #Saudi Arabia Poultry Market Forecast

0 notes

kritikarehani · 3 years

Text

Acute Myeloid Leukemia Market Size, Share, Trends, Epidemiology and Market Forecast 2030

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous malignancy characterized through clonal proliferation and impaired differentiation of myeloid precursors with various outcomes. Quickest-growing cancer happens when the bone marrow begins to form cells that have not yet absolutely matured as blasts. These cells crowd the bone marrow, stopping it from making normal blood cells and leukemia starts to crowd out the normal white blood cells, crimson blood cells, and platelets that the frame desires. In Acute myeloid leukemia, the bone marrow additionally makes strange crimson cells and platelets. As consequence, the blood cells do not develop, and it gets hard to ward off infections.

Acute Myeloid Leukemia Signs and Symptoms

The symptoms of acute myeloid leukemia generally expand over a week and become an increasing number severely. Signs can include anemia, light skin, constant tiredness, joint infections, frequent bleeding, bone pain, and others.

Acute Myeloid Leukemia Epidemiology

Acute Myeloid Leukemia accounts for <3% of all cancer, and 25% of all leukemia in adults. Worldwide, the incidence of Acute Myeloid Leukemia is reported to be highest in the US, Australia, and Western Europe. The incidence has been near stable over the last years. Incidence continuously shows 2 peaks in occurrence in early childhood and later adulthood. From 2000 to 2003, the US incidence rate in people aged <65 years was only 1.8 per 100,000 persons, whereas the incidence rate in people aged 65 years was 17 per 100,000 persons.

The Acute Myeloid Leukemia incidence rate of 3.7 per 100,000 inhabitants in Europe with a 5-year survival rate of 19%. A cross-national study using US and England data found that the overall risk of mortality for Acute Myeloid Leukemia was 23% lower in England compared to that in the US. However, survival difference was similar in subgroups of sex and age at diagnosis.

According to a study, the yearly average incidence rate of leukemia was 3.68/105 during 2003-2007 in Nanjing. There were no significant differences in gender, the incidence rate was the highest in the group aged 80~ years.

Acute Myeloid Leukemia Treatment Options

Acute Myeloid Leukemia is common leukemia affecting adults and poses a major medical challenge with increased mortality and morbidity. Once diagnosed, the treatment needs to start as quickly as possible. The treatment depends on age, risk factors, and the sub-types of Acute Myeloid Leukemia.

The aim of treatment for Acute Myeloid Leukemia is to cure it and achieve remission of leukemia cells. Traditionally, the standardized treatment was chemotherapy which can be divided into intensive chemotherapy and non-intensive. The intensive chemotherapies are two phases of remission induction followed by post-remission consolidation-based therapy. The induction therapy includes drugs such as Cytarabine, Daunorubicin, Idarubicin, and Fludarabine either alone or in combinatorial doses. Consolidation therapy is presented in such cases where induction therapy failed to work, with drugs such as Etoposide, Amsacrine, and Mitoxantrone.

Acute Myeloid Leukemia Market

FLT3 Inhibitors such as Midostaurin and Gilteritinib; IDH Inhibitors such as Enasidenib and Ivosidenib; and Hedgehog pathway inhibitor, such as Glasdegib; BCL-2 inhibitor such as Venetoclax have recently entered the Acute Myeloid Leukemia market as promising targeted therapies with specific genetic mutations. As the first directed agent that works very well in the elderly population with Acute Myeloid Leukemia, Venetoclax and Glasdegib has opened possibilities in the world of targeted therapy. Gilteritinib, Enasidenib, and Ivosidenib were approved explicitly for relapsed and refractory Acute Myeloid Leukemia, with specific genetic mutations. This spell of new drug approvals has altered the Acute Myeloid Leukemia Market and provided new opportunities.

Various companies such as Actinium Pharmaceuticals, AVEO Oncology, Biodesix, Daiichi Sankyo, BioSight, Helsinn Healthcare, Rafael Pharmaceuticals, Otsuka Pharmaceutical, Cyclacel Pharmaceuticals, and others are developing effective therapies, which contribute to the market size of Acute Myeloid Leukemia.

There are many competitors in the development phase for the treatment of AML such as Iomab-B CD45 and Actimab-A CD33 (Actinium Pharmaceuticals), Ficlatuzumab (AVEO Oncology and Biodesix), Devimistat (Rafael Pharmaceuticals), BST236 (BioSight), Bemcentinib (BerGenBio), Pracinostat (Helsinn Healthcare) and others.

#Acute Myeloid Leukemia market #Acute Myeloid Leukemia market share #Acute Myeloid Leukemia market size #Acute Myeloid Leukemia market trends #Acute Myeloid Leukemia market research reports #Acute Myeloid Leukemia epidemiology #Acute Myeloid Leukemia pipeline therapies #Acute Myeloid Leukemia pipeline #Acute Myeloid Leukemia key companies

0 notes

kennethresearch · 3 years

Text

Global Asparaginase Market, June 2021 Report On Analysis 2021, Size, Top Players with Share, Total Revenues, Product Scope, Business Development and Opportunities till 2030

In a recently published report, Global Asparaginase Market report for till 2030. The report further now discusses; the various strategies to be adopted or being adopted by the business players across the globe at various levels in the value chain. In view of the global economic slowdown, we further estimated that China, India, Japan and South Korea to recover fastest amongst all the countries in the Asian market. Germany, France, Italy, Spain to take the worst hit and this hit is expected to regain 25% by the end of 2021- Positive Growth in the economic demand and supply.

U S Market recovers fast; In a release on May 4th 2021, the U.S. Bureau and Economic Analysis and U.S. Census Bureau mention the recovery in the U.S. International trade in March 2021. Exports in the country reached $200 billion, up by $12.4 billion in Feb 2021. Following the continuous incremental trend, imports tallied at $274.5 billion, picked up by $16.4 billion in Feb 2021. However, as COVID19 still haunts the economies across the globe, year-over-year (y-o-y) average exports in the U.S. declined by $7.0 billion from March 2020 till March 2021 whilst imports increased by $20.7 billion during the same time. This definitely shows how the market is trying to recover back and this will have a direct impact on the Healthcare/ICT/Chemical industries, creating a huge demand for Global Asparaginase Market products.

Get Sample Reports Here – https://www.kennethresearch.com/sample-request-10306407

It is also anticipated to grow on account of the growing demand for chemicals from the end users, backed by the increasing consumption of chemicals across different industries and the rising need for advanced chemicals. In India, the production of major chemicals and petrochemicals during the period 2020-2021 was close to 12000 thousand MT. Additionally, between the period 2015-16 and 2019-20, the production of the chemicals and petrochemicals in the nation grew at a CAGR of close to 6%.

Global Asparaginase Market is valued approximately at USD XXX million in 2018 and is anticipated to grow with a healthy growth rate of more than XX % over the forecast period 2019-2026. Asparaginase is an enzyme which catalzes the hydrolysis of l-asparagine to l-aspartic acid and ammonia. Asparaginase products are isolated from different types of bacteria, namely Escherichia coli and Erwinia chrysanthemi. They inhibit protein synthesis in tumor cells by depriving them of the amino acid asparagine. These are used widely in Healthcare industry and Food manufacturing industry as a medication. It is used to treat acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML), and non-Hodgkin’s lymphoma. It is given by injection into a vein, muscle, or under the skin. A pegylated version is also available. As Asparaginase was approved for medical use in the United States in 1978. It is also on the World Health Organization’s List of Essential Medicines, the most effective and safe medicines needed in a health system. Asparaginase is used in the food manufacturing to reduce the formation of acrylamide. Acrylamide is a carcinogen in the starch containing food products such as biscuits and snacks. Thus, the rapidly growing healthcare and food manufacturing industry increase the demand for Asparaginase during the forecast period. As the Food and drinks market in Europe contributed to be the largest manufacturing sector in 2017 with a turnover of USD 1222 billion. The same sector invested USD 3.12 billion in research & development in 2017 which shows a positive sign in the market growth. Further, the rising investments of the market players for the research and development and production of Asparaginase according to the regulatory specification due to the rise in demand further fuels the market growth. However, the side effects of Asparaginase on human body such as mild bone marrow suppression, pancreatitis, anticoagulant factor resulting in stroke and bleeding hinders the market growth.

The regional analysis of global Asparaginase market is considered for the key regions such as Asia Pacific, North America, Europe, Latin America and Rest of the World. North America is the leading/significant region across the world in terms of market share owing to the dominant pharmaceutical industry in the region which is the major industry which uses Asparaginase enzyme. Further rising cases of Leukemia in the region propel the market growth. Whereas, Asia-Pacific is also anticipated to exhibit highest growth rate / CAGR over the forecast period 2019-2026. Factors such as increasing population along with increasing disposable income coupled with growing food manufacturing industry would create lucrative growth prospects for the Asparaginase market across Asia-Pacific region.

Major market player included in this report are: Jazz Pharmaceuticals Plc Shire Plc Medac GmbH Kyowa Hakko Kirin Co., Ltd. Qianhong Bio-pharma Taj Pharmaceuticals Mingxing Pharma Exova SL Pharma Inc United Biotech Pvt. Ltd. Novus Biologicals The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming eight years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within each of the regions and countries involved in the study. Furthermore, the report also caters the detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, the report shall also incorporate available opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and product offerings of key players. The detailed segments and sub-segment of the market are explained below: By Type: Escherichia Coli Erwinia Chrysanthemi Pegylated By Application: Healthcare Food Industry Others By Region: North America U.S. Canada Europe UK Germany Asia Pacific China India Japan Latin America Brazil Mexico Rest of the World

Furthermore, years considered for the study are as follows:

Historical year – 2016, 2017 Base year – 2018 Forecast period – 2019 to 2026

Target Audience of the Global Asparaginase Market in Market Study:

Key Consulting Companies & Advisors Large, medium-sized, and small enterprises Venture capitalists Value-Added Resellers (VARs) Third-party knowledge providers Investment bankers Investor

Download Sample Reports Here – https://www.kennethresearch.com/sample-request-10306407

The report further discusses the market opportunity, compound annual growth rate (CAGR) growth rate, competition, new technology innovations, market players analysis, government guidelines, export and import (EXIM) analysis, historical revenues, future forecasts etc. in the following regions and/or countries:

North America (U.S. & Canada) Market size, Y-O-Y growth, Market Players Analysis & Opportunity Outlook

Latin America (Brazil, Mexico, Argentina, Rest of Latin America) Market size, Y-O-Y growth & Market Players Analysis & Opportunity Outlook

Europe (U.K., Germany, France, Italy, Spain, Hungary, Belgium, Netherlands & Luxembourg, NORDIC, Poland, Turkey, Russia, Rest of Europe) Market size, Y-O-Y growth Market Players Analys & Opportunity Outlook

Asia-Pacific (China, India, Japan, South Korea, Indonesia, Malaysia, Australia, New Zealand, Rest of Asia-Pacific) Market size, Y-O-Y growth & Market Players Analysis & Opportunity Outlook

Middle East and Africa (Israel, GCC (Saudi Arabia, UAE, Bahrain, Kuwait, Qatar, Oman), North Africa, South Africa, Rest of Middle East and Africa) Market size, Y-O-Y growth Market Players Analysis & Opportunity Outlook

About Kenneth Research

Kenneth Research is a reselling agency providing market research solutions in different verticals such as Automotive and Transportation, Chemicals and Materials, Healthcare, Food & Beverage and Consumer Packaged Goods, Semiconductors, Electronics & ICT, Packaging, and Others. Our portfolio includes set of market research insights such as market sizing and market forecasting, market share analysis and key positioning of the players (manufacturers, deals and distributors, etc), understanding the competitive landscape and their business at a ground level and many more. Our research experts deliver the offerings efficiently and effectively within a stipulated time. The market study provided by Kenneth Research helps the Industry veterans/investors to think and to act wisely in their overall strategy formulation

Kenneth Research

Email : [email protected]

Phone: +1 313 462 0609

0 notes

riyaus · 3 years

Text

Leukemia Therapeutics Market Competitive Analysis 2021

Leukemia Therapeutics Market 2021

The latest research report on Leukemia Therapeutics market Presents a Comprehensive investigation of the market size, regional Overview, revenue estimates, upcoming challenges in the industry, current statistics with future prediction and COVID-19 Impact.

Get the Sample report: https://straitsresearch.com/report/Leukemia Therapeutics-Market/request-sample

The Major Manufacturers Covered in this Report: Novartis (Switzerland), AbbVie (US), Bristol-Myers Squibb (US), Hoffmann-La Roche (Switzerland), Sanofi (France), Pfizer (US), Amgen (US), Gilead Sciences (US), Takeda Pharmaceutical (Japan), Celgene (US) ...

Market Segmentation: By Type Acute lymphocytic leukemia (ALL), Chronic lymphocytic leukemia (CLL), Acute myeloid leukemia (AML), Chronic myeloid leukemia (CML), By Treatments Targeted drugs & immunotherapy, Chemotherapy, By Mode of Administration Oral, Injectables

#Leukemia Therapeutics Market #Leukemia Therapeutics Market 2021

0 notes

cool-akashy-maximize · 3 years

Text

Global Leukemia Therapeutics Market : Industry Analysis and Forecast (2019-2027)

Global Leukemia Therapeutics Market was valued at US$ 11.32 Bn in 2019 and is expected to reach US$ 19.2 Bn by 2027, at a CAGR of 7.84 % during the forecast period.

The report includes an analysis of the impact of COVID-19 lockdown on the revenue of market leaders, followers, and disruptors. Since the lockdown was implemented differently in various regions and countries; the impact of the same is also seen differently by regions and segments. The report has covered the current short-term and long-term impact on the market, and it would help the decision-makers to prepare the outline and strategies for companies by region. Global Leukemia Therapeutics MarketGlobal Leukemia Therapeutics Market Dynamics:

Increased prevalence of cancer especially blood cancer across the globe is leading to increasing demand for effective treatments, which is the driving factor for market growth. Increase in expenditure on the development of novel treatment and developing health infrastructure is further driving the market growth. Additionally, the growth in survival rate and minimum side effects of novel treatment such as stem cell therapy, bone marrow transplant has open new avenues for market growth. Also, increased exposer to chemical mutation, changing dietary habits, and the living style of the population is further pushing the market growth.

The lack of early diagnosis and awareness among the public are leading challenges in the market for leukemia therapeutics. Furthermore, redefining the drug lifecycle roadmap is a major challenge for drug innovators. However, breakthrough therapy designations and accelerated approvals granted by regulatory bodies like the FDA would offer lucrative market opportunities for the drug innovators. Segment Analysis of the Global Leukemia Therapeutics Market:

Based on treatment type, chemotherapy led the segment in 2019. Because of its ability to kill cancerous cells or inhibiting their proliferation and maintain a normal level of lymphocytes of chemotherapy, is driving the market growth. Similarly, the increased survival rate of the patients treated with chemotherapy is again fueling its demand.

On the basis of the type of leukemia, acute lymphocytic leukemia is dominating the segment and has accounted for maximum market share. Owing to the rising condition of cancerous cells, acute leukemia is driving the segment growth. Increasing smoking habits, exposure to chemicals, radiation, and cases with other blood-related disorders are again driving the segment growth. Regional Insights of the Global Leukemia Therapeutics Market:

In terms of region, North America followed by Europe dominates the global leukemia therapeutics market owing to the growing incidence of cancer and increasing aging population. The APAC is expected to show a high growth rate because of the increasing incidence of cancer. China and India are expected to be the fastest-growing leukemia markets in the Asia Pacific region. Some of the key driving forces for the leukemia therapeutic market in emerging economies are increasing R&D investment, a large pool of patients, and growing government funding.

Key developments in leukemia therapeutics market: In February 2018, Sanofi announced to discard the mid-stage exertion on ALL therapy for the anti-CD38 antibody isatuximab. Also, Erytech Pharma broadened the scope of eryaspase (GRASPA) growth for solid tumors further clinical studies in triple-negative breast cancer.

The objective of the report is to present a comprehensive assessment of the market and contain thoughtful insights, facts, historical data, industry-validated market data and projections with a suitable set of assumptions and methodology. The report also helps in understanding Global Leukemia Therapeutics Market dynamics, structure by identifying and analyzing the market segments and project the global market size. Further, the report also focuses on the competitive analysis of key players by product, price, financial position, product portfolio, growth strategies, and regional presence. Scope of the Global Leukemia Therapeutics Market Report:

Global Leukemia Therapeutics Market, by Type of Leukemia

• Chronic Myeloid Leukemia • Chronic Lymphocytic Leukemia • Acute Lymphocytic Leukemia • Acute Myeloid Leukemia

Global Leukemia Therapeutics Market, by Treatment Type

• Targeted Drugs & Immunotherapy • Chemotherapy

Global Leukemia Therapeutics Market, by Molecule Type

• Small Molecules • Biologics

Global Leukemia Therapeutics Market, by Mode of Administration

• Oral Mode • Injectable Mode

Global Leukemia Therapeutics Market, by Gender

• Males • Females

Global Leukemia Therapeutics Market, by Region

• North America • Europe • Asia Pacific • Middle East and Africa • South America Key Players Operating in the Global Leukemia Therapeutics Market:

• Novartis AG • AbbVie • Bristol-Myers Squibb • Hoffmann-La Roche • Sanofi • Pfizer • Amgen • Gilead Sciences • Takeda • Celgene • AbARIAD Pharmaceuticals, Inc. • F. Hoffmann-La Roche Ltd. • Genzyme Corporation • GlaxoSmithKline plc. • Teva Pharmaceuticals • Allergan, • AstraZeneca, • F. Hoffmann-La Roche Ltd, • Pfizer Inc., • Merck KGaA, Merck & Co., Inc.,

For More Information Visit @: This Report Is Submitted By : Maximize Market Research Company Customization of the report: Maximize Market Research provides free personalized of reports as per your demand. This report can be personalized to meet your requirements. Get in touch with us and our sales team will guarantee provide you to get a report that suits your necessities.

About Maximize Market Research: Maximize Market Research provides B2B and B2C research on 20,000 high growth emerging opportunities & technologies as well as threats to the companies across the Healthcare, Pharmaceuticals, Electronics & Communications, Internet of Things, Food and Beverages, Aerospace and Defense and other manufacturing sectors.

0 notes

cool-cillian-murphy · 3 years

Text

Asparaginase Market - A Story of Very Rapid Development

Latest released the research study on Global Asparaginase Market, offers a detailed overview of the factors influencing the global business scope. Asparaginase Market research report shows the latest market insights with upcoming trends and breakdown of the products and services. The report provides key statistics on the market status, size, share, growth factors of the Asparaginase. The study covers emerging player’s data, including: competitive situation, sales, revenue and global market share of top manufacturers are Porton Biopharma (England), Jazz Pharmaceuticals (Ireland),Takeda (Japan),ERYTECH Pharma (France),Qianhong Bio-pharma (China),Mingxing Pharma (China),Medac GmbH (Germany),Kyowa Hakko Kirin (Japan),Alize Pharma (France),Guangzhou Baiyuan Shanmingxing Pharmaceutical (China),.

Free Sample Report + All Related Graphs & Charts @ : https://www.advancemarketanalytics.com/sample-report/6507-global-and-united-states-asparaginase-market Keep yourself up-to-date with latest market trends and changing dynamics due to COVID Impact and Economic Slowdown globally. Maintain a competitive edge by sizing up with available business opportunity in Global Asparaginase Market various segments and emerging territory.

Asparaginase Market Overview Asparaginase is a microbial product derived from Escherichia coli or from Erwinia chrysanthemi. Asparaginase is a white crystalline powder which contains the enzyme L-asparagine amidohydrolase derived from Escherichia. L-asparaginase has been reported to interface with the interpretation of thyroid function tests. It contains fungi from extreme environments which lead to the development of new chemotherapeutic treatment methods that have fewer side- effects than others. The general trade names for l-asparaginase in the United States are Elspar and Kidrolase. Market Drivers Growing Number of Cancer Patients in the United States

Increase Number Patients with Acute Lymphocytic Leukemia

Market Trend High Adoption to Treat Childhood Cancer Treatments

Increase Demand for Human Brain Function and In Ammonia Physiology

Restraints Increasing Cost of the Asparaginase Drugs Is Hamper the Growth of the Market Challenges Increasing Number of Side Effects Such As Fever, Vomits, Allergic Reaction and Others The Global Asparaginase Market segments and Market Data Break Down are illuminated below: by Type (E. Coli Asparaginase, Erwinia Asparaginase, Pegylated Asparaginase), Application (Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia), Distribution Channel (Pharmacies, Convenience Store, Online Sales, Other) Region Included are: North America, Europe, Asia Pacific, Oceania, South America, Middle East & Africa

Country Level Break-Up: United States, Canada, Mexico, Brazil, Argentina, Colombia, Chile, South Africa, Nigeria, Tunisia, Morocco, Germany, United Kingdom (UK), the Netherlands, Spain, Italy, Belgium, Austria, Turkey, Russia, France, Poland, Israel, United Arab Emirates, Qatar, Saudi Arabia, China, Japan, Taiwan, South Korea, Singapore, India, Australia and New Zealand etc. Enquire for customization in Report @: https://www.advancemarketanalytics.com/enquiry-before-buy/6507-global-and-united-states-asparaginase-market Strategic Points Covered in Table of Content of Global Asparaginase Market:

Chapter 1: Introduction, market driving force product Objective of Study and Research Scope the Asparaginase market

Chapter 2: Exclusive Summary – the basic information of the Asparaginase Market.

Chapter 3: Displaying the Market Dynamics- Drivers, Trends and Challenges & Opportunities of the Asparaginase

Chapter 4: Presenting the Asparaginase Market Factor Analysis, Post COVID Impact Analysis, Porters Five Forces, Supply/Value Chain, PESTEL analysis, Market Entropy, Patent/Trademark Analysis.

Chapter 5: Displaying the by Type, End User and Region/Country 2015-2020

Chapter 6: Evaluating the leading manufacturers of the Asparaginase market which consists of its Competitive Landscape, Peer Group Analysis, BCG Matrix & Company Profile

Chapter 7: To evaluate the market by segments, by countries and by Manufacturers/Company with revenue share and sales by key countries in these various regions (2021-2026)

Chapter 8 & 9: Displaying the Appendix, Methodology and Data Source Finally, Asparaginase Market is a valuable source of guidance for individuals and companies in their decision framework. Data Sources & Methodology The primary sources involves the industry experts from the Global Asparaginase Market including the management organizations, processing organizations, analytics service providers of the industry’s value chain. All primary sources were interviewed to gather and authenticate qualitative & quantitative information and determine the future prospects. In the extensive primary research process undertaken for this study, the primary sources – Postal Surveys, telephone, Online & Face-to-Face Survey were considered to obtain and verify both qualitative and quantitative aspects of this research study. When it comes to secondary sources Company's Annual reports, press Releases, Websites, Investor Presentation, Conference Call transcripts, Webinar, Journals, Regulators, National Customs and Industry Associations were given primary weight-age. For Early Buyers | Get Up to 20% Discount on This Premium Report: https://www.advancemarketanalytics.com/request-discount/6507-global-and-united-states-asparaginase-market What benefits does AMA research studies provides?

· Latest industry influencing trends and development scenario

· Open up New Markets

· To Seize powerful market opportunities

· Key decision in planning and to further expand market share

· Identify Key Business Segments, Market proposition & Gap Analysis

· Assisting in allocating marketing investments

Definitively, this report will give you an unmistakable perspective on every single reality of the market without a need to allude to some other research report or an information source. Our report will give all of you the realities about the past, present, and eventual fate of the concerned Market.

Thanks for reading this article; you can also get individual chapter wise section or region wise report version like North America, Europe or Asia. About Author:

Advance Market Analytics is Global leaders of Market Research Industry provides the quantified B2B research to Fortune 500 companies on high growth emerging opportunities which will impact more than 80% of worldwide companies' revenues.

Our Analyst is tracking high growth study with detailed statistical and in-depth analysis of market trends & dynamics that provide a complete overview of the industry. We follow an extensive research methodology coupled with critical insights related industry factors and market forces to generate the best value for our clients. We Provides reliable primary and secondary data sources, our analysts and consultants derive informative and usable data suited for our clients business needs. The research study enable clients to meet varied market objectives a from global footprint expansion to supply chain optimization and from competitor profiling to M&As. Contact Us:

Craig Francis (PR & Marketing Manager) AMA Research & Media LLP Unit No. 429, Parsonage Road Edison, NJ New Jersey USA – 08837 Phone: +1 (206) 317 1218 [email protected] Connect with us at https://www.linkedin.com/company/advance-market-analytics https://www.facebook.com/AMA-Research-Media-LLP-344722399585916 https://twitter.com/amareport

0 notes

leonfrancisblog · 3 years

Text

Hemato Oncology Testing Market Global Trends, Growth, Opportunities, Market Size Forecast to 2027|Major Competitors Abbott Laboratories, QIAGEN, Thermo Fisher Scientific Inc., Illumina, Inc., Bio-Rad Laboratories, Inc., MolecularMD, ArcherDx, Inc

Hemato oncology testing market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, company strengths and weaknesses, product launch, clinical trials pipelines, product approvals, patents, product width and breadth, application dominance, technology lifeline curve. The above data points provided are only related to the companies’ focus related to hemato oncology testing market This hemato oncology testing market report provides details of market share, new developments, product pipeline analysis, impact of domestic and localised market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, product approvals, strategic decisions, product launches, geographic expansions, and technological innovations in the market. To understand the analysis and the market scenario contact us for an Analyst Brief our team will help you create a revenue impact solution to achieve your desired goal.

Increasing cases of hematologic cancer and growing awareness about the advanced treatment therapies among population will drive the market growth. Rising cases of myeloma cancers and lymphoma will also affect the market positively. Leukemia patients are constantly keeping track on the status of minimal residual disease which is also expected to affect the market positively. Favourable reimbursement policy on the hemato oncology testing products will also enhance the market growth. On the other hand, rising collaboration between manufacturer, increasing conferences on personalized medicines, and growing demand for advanced treatment options will also create new opportunities for the hemato oncology testing market in the forecast period of 2020- 2027.

Global Hemato Oncology Testing Market By Product & Services (Services, Assay Kits), Cancer Type (Leukemia, Lymphoma, Other Cancers), Technology (PCR, IHS, NGS, Cytogenetics, Other), End- Users (Clinical Laboratories, Hospitals, Academic & Research Institutes, Others), Country (U.S., Canada, Mexico, Brazil, Argentina, Rest of South America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific, Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa), Market Share Forecast to 2027Hemato Oncology Testing market is expected to gain market growth in the forecast period of 2020 to 2027. Data Bridge Market Research analyses the market to growat a CAGR of 14.10% in the above-mentioned forecast period. Increasing cases of leukemia and increasing demand for personalized medicines will create new opportunities for this market in the forecast period of 2020- 2027.Hemotology is that route of medicine which deals with the treatment, causes, and other problems associated with the blood. On the other hand, oncology is connected with the study of the treatment, diagnosis, and other problem associated with cancer. Hematolo-oncology is the method used to treat diseases and blood disorders and cancers.

Get An Sample Request on Get an Sample Request on Global Hemato Oncology Testing Market: https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-hemato-oncology-testing-market

Hemato Oncology Testing Market Country Level Analysis:

Hemato oncology testing market is analyzed and market size insights and trends are provided product & services, cancer type, technology and end use as referenced above.

The country section of the hemato oncology testing market report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, disease epidemiology and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of sales channels are considered while providing forecast analysis of the country data. The countries covered in the hemato oncology testing market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific in the Asia-Pacific, Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa as a part of Middle East and Africa, Brazil, Argentina and Rest of South America as part of South America. North America dominates the hemato oncology testing market due to favourable reimbursement policy for hemato oncology testing products while Asia-Pacific is expected to grow at the highest growth rate in the forecast period 2020 to 2027 due to increasing patient population.

Healthcare Infrastructure growth Installed base and New Technology Penetration:

Hemato oncology testing market also provides you with detailed market analysis for every country growth in healthcare expenditure for capital equipment’s, installed base of different kind of products for hemato oncology testing market, impact of technology using life line curves and changes in healthcare regulatory scenarios and their impact on the hemato oncology testing market. The data is available for historic period 2010 to 2018.

Global Hemato Oncology Testing Market Scope and Market Size:

Hemato oncology testing market is segmented of the basis of product & services, cancer type, technology and end use. The growth amongst these segments will help you analyze meagre growth segments in the industries, and provide the users with valuable market overview and market insights to help them in making strategic decisions for identification of core market applications.

Based on product & services, hemato oncology testing market is segmented into services, and assay kits.

On the basis of cancer type, the hemato oncology testing market is classified into leukemia, lymphoma, and other cancers. Leukemia is further divided into acute myeloid leukemia, acute lymphocytic leukemia, and other leukemia. Lymphoma is segmented into non-Hodgkin lymphoma and Hodgkin lymphoma. The hemato oncology testing market is also segmented on the basis of technology as PCR, IHS, NGS, cytogenetic, and other. The global hemato oncology testing market has also been segmented based on the end use into clinical laboratories, hospitals, academic & research institutes, and others.

The major players covered in the hemato oncology testing market report are F. Hoffmann-La Roche Ltd, Abbott Laboratories, QIAGEN, Thermo Fisher Scientific Inc., Illumina, Inc., Bio-Rad Laboratories, Inc., MolecularMD, ArcherDx, Inc., ARUP Laboratories., Invivoscribe, Inc., CORE Diagnostics, Genoptix, Inc., GenPath, NeoGenomics Laboratories, Inc., Siemens AG, among other players domestic and global. Market Share data is available for Global, North America, Europe, Asia-Pacific, Middle East and Africa and South America separately. DBMR analysts understand competitive strengths and provide competitive analysis for each competitor separately.

Get Table of Content https://www.databridgemarketresearch.com/toc/?dbmr=global-hemato-oncology-testing-market

Reasons for buying this Global Hemato Oncology Testing Market:

Laser Capture Global Hemato Oncology Testing Market aids in understanding the crucial product segments and their perspective.

Initial graphics and exemplified that a SWOT evaluation of large sections supplied from the Laser Capture Global Hemato Oncology Testing Market.

Even the Laser Capture Global Hemato Oncology Testing Market economy provides pin line evaluation of changing competition dynamics and retains you facing opponents.

This report provides a more rapid standpoint on various driving facets or controlling Medical Robotic System promote advantage.

This worldwide Locomotive report provides a pinpoint test for shifting dynamics that are competitive.

The key questions answered in this report:

What will be the Market Size and Growth Rate in the forecast year?

What is the Key Factors driving Laser Global Hemato Oncology Testing Market?

What are the Risks and Challenges in front of the market?

Who are the Key Vendors in Global Hemato Oncology Testing Market?

What are the Trending Factors influencing the market shares?

What is the Key Outcomes of Porter’s five forces model

Access Full Report https://www.databridgemarketresearch.com/reports/global-hemato-oncology-testing-market

Browse Related Report:

North America Metabolic Testing Market

Pharmaceutical Equipment Testing Market

Sterility Testing Market

About Us:

Data Bridge Market Research set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market

Contact:

Data Bridge Market Research

Tel: +1-888-387-2818

Email: [email protected]

#Market by Type Market Development Market Forecast Market Size Future Innovation Market Future Trends Market Share Market Demand Market Growt

0 notes

kenresearch1 · 8 months

Text

Top 3 US Pharmaceutical Companies and Their Strategies in US Acute Myeloid Leukemia Market

Buy Now

US Acute Myeloid Leukemia Market is growing due to advancement in treatment approaches, increase healthcare costs and expenditure, growing investments in Research and Development, and a constant growth in population.

Story Outline

Pfizer Inc.- An American multinational company with the highest annual revenue of around 100 billion US$ in 2022 in the drug market. The company has made significant contributions to the US Acute Myeloid Leukemia Market through a sophisticated, robust, agile manufacturing infrastructure and investment in research and development.

Brystol Myers Squibb- One of the largest American pharmaceutical companies which consistently ranks on the Fortune 500 list of the largest US corporations. The company’s mission is to discover, develop, and deliver innovative medicines that help patients as well as prevail over serious diseases.

Novartis AG- The company with the fourth-largest revenue in the drug market which is focused to deliver high-value medicine that alleviate society’s greatest disease burdens through technology leadership in R&D and novel access approaches.

The US Acute Myeloid Leukemia Market is expected to grow at CAGR of 10.5% in the forecast period 2022-2028.

The Acute Myeloid Leukemia Market of US is driving growth at an amazing level. This surge is a result of advancement in treatment approaches, increases healthcare costs and expenditure, growing investments in Research and Development, and a constant growth in population.

Various pharmaceutical companies are actively shaping this growing market with their strategies and innovations.

This article provides an in-depth look at major pharmaceutical companies with their strategies and innovations.

1.Pfizer Inc.

Click here: To know more about Pfizer Inc.

Pfizer Inc. is an American multinational pharmaceutical company and headquartered at The Spiral in Manhattan, New York City. The company has made significant contributions to the US Acute Myeloid Leukemia Market through a sophisticated, robust, agile manufacturing infrastructure and investing in research and development.

The company employs more than 30,000 employees worldwide, have 35+ manufacturing sites, 300+ external suppliers, and have reached more than 180 countries. Pfizer tops the list of drug market by achieving a revenue of approx. 100 billion USD in 2022.

Pfizer has made significant contributions to the US acute Myeloid Leukemia Market. Some notable contributions are, in April 2017, the development and approval of a targeted therapy called “Rydapt”, which is an oral kinase inhibitor that targets multiple enzymes, including FLt3, which is often mutated in AML patients. The drug was approved by FDA in April 2017 for use in combination with Chemotherapy.

Furthermore, MYLOTARG is approved in combination with daunorubicin and cytarabine for the treatment of patients aged 15 and above with previously untreated, de novo, CD33-positive acute myeloid leukemia (AML), except Acute Promyelocytic Leukemia (APL).

The company’s purpose is “Breakthroughs that change patients' lives—fuels everything we do and reflects our passion for building on our legacy as one of the greatest contributors of good to the world.

The company says that its purpose ensures that its patients remain at the center of all that they do. They live with their purpose by sourcing the best science in the world; partnering with others in the healthcare system to improve access to their medicines.

Pfizer believes in growing partnerships with innovators to initiate forward great science and continually seek new partners that are actively researching bold scientific ideas. In December 2022, Pfizer announced its collaboration with Gero’s machine learning technology platform to discover potential therapeutic targets for fibrotic using large-scale human-based data.

Pfizer’s continuous clinical trials and collaboration with healthcare institutions and research organizations has majorly contributed in advancing Acute Myeloid Leukemia Market and the development of novel treatment strategies.

2.Bristol Myers Squibb

Click here: To Download a Sample Report

The Bristol Myers Squibb Company, is an American multinational pharmaceutical company headquartered in Princeton, New Jersey. BMS is one of the world’s largest pharmaceutical companies and consistently ranks on the Fortune 500 list of the largest US corporations.

The company employs more than 34,000 across more than 86 locations worldwide. The company’s revenue in 2022 was approximately 46 bn USD.

Their mission is to discover, develop, and deliver innovative medicines that help patients as well as prevail over serious diseases. Bristol believes in the power of science to address some most challenging diseases of today's world.

Bristol Myers is majorly known for its contributions to oncology, and immunology and its involvement in Acute Myeloid Leukemia Market with its broader focus on cancer treatments.

The significant development of BMS can be noted from June 2021, Bristol Myers Squibb received approval from European Commission for Onureg, a Frontline oral maintenance therapy for adult patients with acute Myeloid Leukemia who achieved their first complete remission (CR) or CR with incomplete blood count recovery following intensive induction chemotherapy. Onureg is expected to increase sales and product revenue, thereby increasing the US Acute Myeloid Leukemia Market growth.

Furthermore, the strategic cooperation between Evotec and Bristol Myers Squibb has grown in order to create a pipeline for programs addressing more neurological illnesses. In order to find altering therapies for a variety of neurodegenerative disorders, the firms started working together in 2016. The eight-year extension is intended to strengthen the strategic partnership even more.

3.Novartis AG

Click Here : To Download a Custom Report

Novartis AG is a healthcare company that majorly focuses on the discovery, development, manufacture and marketing of prescription and generic pharmaceutical and eye care products. Novartis offers generic medicines and biosimilars through Sandoz. The company conducts its research through The Novartis Institute for Biomedical Research (NIBR).

Novartis is one of the largest pharmaceutical companies in the world and the fourth largest by revenue in 2022, which was approx. 50.500 billion USD.

The company is functioning in more than 150 locations with around 1,10,000 employees working worldwide.

Novartis's strategy as a focused medicines company is to deliver high-value medicine that alleviates society’s greatest disease burdens through technology leadership in R&D an novel access approaches.

Novartis contribution to Acute Myeloid Leukemia Market includes, FDA approval of Novartis Scemblix (asciminib), with novel mechanism of action for the treatment of Leukemia in October,2021.

Furthermore, through their open approach Novartis is focusing on new technologies to develop next generation therapeutics. Currently, Novartis is working with Orionis Bioscience to find new targets at a genome-wide scale.

By combining development and drug discovery with innovation, they aim to achieve tenuous targets and to launch novel small molecule therapy for Acute Myeloid Leukemia patients more quickly. Thus driving a steered growth for the US Acute Myeloid Leukemia Market.

0 notes

top-market-research · 3 years

Text

Acute Myeloid Leukemia Therapeutics Market Share, Industry Analysis, Forecast and Global Research Report

The in-depth study on the Acute Myeloid Leukemia Therapeutics Market covers a comprehensive analysis of the historical data, present and emerging market trends, technological advancements, and the overall market scenario. The report titled Global Acute Myeloid Leukemia Therapeutics Market published by Reports and Data analyze the current market scene, market share, growth rate, future trends, market drivers, opportunities, and challenges, risks and entry barriers. The report includes a comprehensive assessment of the positive and negative factors influencing the growth and trends of the market.

The global Acute Myeloid Leukemia Therapeutics market is forecasted to grow at a rate of 13.1% from USD 1.46 billion in 2019 to USD 3.56 billion in 2027.

The report considers COVID-19 as a key market contributor. The report describes in detail the effect of the COVID-19 pandemic on the major segments of the Acute Myeloid Leukemia Therapeutics Market sector. The pandemic has affected the Acute Myeloid Leukemia Therapeutics Market sector dynamically and the report covers the changes in demands and trends in the market. The report studies threats and challenges the industry players will have to face due to the changes induced by COVID-19 pandemic. Furthermore, the report provides a detailed description of the COVID-19 impact on the overall growth of the market.

Get a sample of the report @ https://www.reportsanddata.com/sample-enquiry-form/3354

The report is an all-inclusive document containing a thorough assessment of the top market players operating in the industry and controlling a significant share of the market. A breakdown analysis of the competitive landscape comprising of expansion tactics and strategic alliances adopted by the companies are offered in the report. The report covers a detailed assessment of mergers & acquisitions, product launches, partnerships & agreements, joint ventures, and collaborations, among others happening between the prominent industry players.

Key Players Operating in the Market and Profiled in the Report are:

Ambit Biosciences Corporation, Cephalon, Clavis Pharma, Eisai, Genzyme Corporation, Sunesis Pharmaceuticals, Takeda Pharmaceuticals, Amgen, Celgene, and Sanofi have been profiled in the report. They are the major manufacturers of the Regimen.

Request a discount on the report @ https://www.reportsanddata.com/discount-enquiry-form/3354

The reports presents encyclopedic company profiles of the leading participants of the Acute Myeloid Leukemia Therapeutics Market industry to allow the reader to gain a better understanding of the competitive landscape to help in formulating better decisions and investment strategies. It also covers SWOT analysis and Porter’s Five Forces analysis to impart a better understanding of the key players operating in the market.

Additionally, the report consists a detailed analysis of the segmentation of the Acute Myeloid Leukemia Therapeutics Market based on product types and end-use/application offered in the Acute Myeloid Leukemia Therapeutics Market. The report an exhaustive summary of the product and application landscape of the industry along with details about the segmented expected to show significant growth in the upcoming years.

Based on the product type, the Acute Myeloid Leukemia Therapeutics Market is segmented into

Chemotherapy

Radiation therapy

Stem Cell Transplant

Targeted Therapy

Based on the application spectrum, the Acute Myeloid Leukemia Therapeutics Market is segmented into

Hospital

Retails Drug Stores

Ambulatory Care Centers

Clinics

To know more about the report, visit @ https://www.reportsanddata.com/report-detail/acute-myeloid-leukemia-therapeutics-market

The report provides an extensive detailing of the market share and size of the Acute Myeloid Leukemia Therapeutics Market industry in the key geographical regions. Based on the regional breakdown, the market is segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa.

In-depth regional analysis covers:

North America (U.S., Canada, Mexico)

Europe (U.K., Italy, Germany, France, Rest of EU)

Asia Pacific (India, Japan, China, South Korea, Australia, Rest of APAC)

Latin America (Chile, Brazil, Argentina, Rest of Latin America)

Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of MEA)

Request customization of the report @ https://www.reportsanddata.com/request-customization-form/3354

Browse Related Reports –

Photomedicine Market Growth

Cervical Cancer Diagnostic Market

Photomedicine Market Drivers

Bioinformatics Market Manufacturers

Blood Culture Tests Market Revenue

Thank you for reading our report. For further query or inquiry, kindly get in touch with us and our team will ensure your requirements for the reports are met.

#Leukemia Therapeutics Market

0 notes

industryjournals · 4 years

Text

Hedgehog Pathway Inhibitors Market report 2019- 2026 potential growth, share, demand and forecast

The market intelligence report on the Hedgehog Pathway Inhibitors market will offer stakeholders valuable insights into their target consumers and geographies to devise more promising marketing strategies for the forecast years from 2019 to 2026. Above all, the report will empower business owners and professionals to gain vital information about potential consumers and where they can find them. Apart from this, the literature emphasizes how major vendors operating in the Hedgehog Pathway Inhibitors market are optimizing their marketing campaigns. With an exclusive coverage of the top vendors, the study arms business owners with extensive knowledge of the local market as well as improved ability to locate potential consumers and retain existing consumers.

Market Size – USD 961.7 Million in 2026, Market Growth - CAGR of 10.3%, Market Trends – Product launches and R&D for Hedgehog pathway inhibitors

Get a Free PDF Sample Copy (including TOC, Tables, and Figures) at: https://www.reportsanddata.com/sample-enquiry-form/2130

In market segmentation by manufacturers, the report covers the following companies-

Pfizer Inc., F. Hoffmann-La Roche AG, Sun Pharmaceutical Industries Limited, Infinity Pharmaceuticals, Max Biopharma Inc, PellePharm Inc., Takeda Pharmaceutical Company Ltd, Mayne Pharma Group Limited, and Bristol-Myers Squibb Company.

For the purpose of this report, Reports and Data has segmented the Hedgehog pathway inhibitors market on the basis of product type, pathway type, application, route of administration, patient use, and region:

Product Type Outlook (Revenue, USD Million; 2016-2026)

Glasdegib

Vismodegib

Sonidegib

Itraconazole

Oxysterol

Saridegib

Pathway Type Outlook (Revenue, USD Million; 2016-2026)

Canonical Hedgehog Signaling

Non-Canonical Hedgehog Signaling

Application Outlook (Revenue, USD Million; 2016-2026)

Basal Cell Carcinoma

Acute Myeloid Leukemia

Medulloblastoma

Gorlin Syndrome

Others

View Exhaustive Market Research Press Release@ https://www.reportsanddata.com/press-release/global-hedgehog-pathway-inhibitors-market

Route of Administration Outlook (Revenue, USD Million; 2016-2026)

Oral

Topical

Patient Use Outlook (Revenue, USD Million; 2016-2026)

Adult

Children

Regional Outlook (Revenue in USD Million; 2016–2026)

North America

Europe

Asia Pacific

Middle East & Africa

Latin America

The report not only empowers companies and professionals to understand the significant characteristics of the target market but also the communication preferences. The audience can get the estimated size of the market calculated on the basis of the number of sales in a specific region. By offering insights into the profit margin, the study aims at improving the communication between companies and potential customers. Armed with all essential information on recent developments in the competitive landscape, such as a joint venture, collaboration, acquisition and merger and product launch, the study enables business owners to build a robust portfolio of their best buyers.

The objectives of the report are:

– To examine and forecast the market size of the Hedgehog Pathway Inhibitors Industry in the global market. – To study the global key players with a focus on the SWOT analysis, value and global market share for leading players.

– To analyze the market by type, end use, and region to draw a forecast for the years 2019–2026.

– To assess the market potential and advantage, opportunities and challenges, restraints and risks faced by global key regions.

– To decipher significant trends and elements driving or confining the market growth.

– To analyze the opportunities in the market for stakeholders by identifying the high growth segments. – To critically analyze each submarket by evaluating individual growth trends and their role in the market.

– To examine competitive developments such as agreements, business expansions, product launches, and possessions in the market.

– To outline the key players and comprehensively analyze their growth strategies.

Browse the comprehensive TOC and data tables @ https://www.reportsanddata.com/report-detail/hedgehog-pathway-inhibitors-market

The research provides answers to the following key questions:

What type of customers are purchasing the products and services from companies operational in the Hedgehog Pathway Inhibitors market?

What will be the roadmap for product manufacturers engaged in the Hedgehog Pathway Inhibitors industry for the forecast years from 2019 to 2026?

What are the recent advancements and feats by key competitors to look out for during the estimated period?

What are the major trends influencing customers’ lifestyles and consequently, their purchasing activities?

How can brands best appeal to the customers they intend to target?

When, where, and how can the customers use or consume the products or services?

About Reports and Data

Reports and Data is a market research and consulting company that provides syndicated research reports, customized research reports, and consulting services. Our solutions purely focus on your purpose to locate, target and analyze consumer behavior shifts across demographics and industries to help clients make smarter business decisions. We offer market intelligence studies ensuring relevant and fact-based research across multiple industries including Healthcare, Technology, Chemicals, Power, and Energy. We consistently update our research offerings to ensure that our clients are aware of the latest trends existent in the market. Reports and Data has a strong base of experienced analysts from varied areas of expertise.

Contact Us: John Watson Head of Business Development Direct Line: +1-212-710-1370 E-mail: [email protected] Reports and Data | Web: www.reportsanddata.com

#Hedgehog Pathway Inhibitors Market Trends #Hedgehog Pathway Inhibitors Market #Hedgehog Pathway Inhibitors Market Application #Hedgehog Pathway Inhibitors Market Types #Hedgehog Pathway Inhibitors Market Outlook #Hedgehog Pathway Inhibitors Market Vendors #Hedgehog Pathway Inhibitors Market Overview #Hedgehog Pathway Inhibitors Market Analysis #Reports and Data #Hedgehog Pathway Inhibitors Market Share Or Size

0 notes

pharmaphorumuk · 5 years

Text

Astellas gets EU approval for AML drug Xospata

The European Commission has approved Astellas’ Xospata (gilteritinib) for patients with relapsed or refractory FLT3-positive acute myeloid leukemia (AML), cementing its lead over a rival drug from Daiichi Sankyo.

Xospata, a FLT3 inhibitor, received an accelerated review, and the approval follows a positive CHMP recommendation in September.

The FLT3 mutation is expressed in about 30% of AML patients and is associated with a worse prognosis, higher relapse rate, faster progression and shorter overall survival, and FLT3 inhibitors have been pitched as a major advance in treatment for patients.

Xospata has been shown in the ADMIRAL clinical trial to improve overall survival compared to salvage chemotherapy, the standard second-line treatment option, with a median OS of 9.3 months for the Astellas drug versus 5.6 months for chemo.

It has been shown to work in two FLT3 mutations – namely ITD and TKD – while quizartinib only targets ITD but has greater potency against that target.

“AML is a rare cancer and patients with a FLT3 mutation have a particularly poor prognosis, with a median survival of less than six months following treatment with salvage chemotherapy,” said Giovanni Martinelli, an investigator in the ADMIRAL trial. “Gilteritinib is a new and clinically meaningful treatment option that provides a welcome advance for patients and health care professionals across the European Union.”

Xospata was cleared in the US and Japan last year, and the CHMP backing gives Astellas another leg up in the market over Daiichi Sankyo and its FLT3 inhibitor quizartinib.

The EMA is also in the midst of an accelerated review of quizartinib, but Daiichi Sankyo suffered a big setback last year when the FDA rejected its marketing application, just a few days after it claimed its first approval in Japan. The FDA verdict came after its advisory committee voted against the drug on the grounds that the clinical trial data in its marketing application may not be reliable.

Xospata and quizartinib have reached the market after Novartis’ first-to-market FLT3-targeting drug Rydapt (midostaurin), which was approved in both the US and Europe for newly-diagnosed FLT3-positive AML in combination with chemotherapy in 2017.

Astellas and Daiichi Sankyo’s drugs are being positioned initially as second-generation FLT3 inhibitors that build on the activity seen with Rydapt and extend the use of the class into second-line treatment.

However, both companies have aspirations to extend their use into the first-line setting and challenge Rydapt directly. There’s also more potential competition on the way from AROG Pharma, whose FLT3 inhibitor crenolanib is in late-stage development for newly-diagnosed as well as relapsed/refractory AML.

Sales of Novartis’ drug are too small to warrant their own line in the company’s quarterly results statements, but analysts have previously suggested that peak sales of the drug will be in the $250 to $300 million range.

Astellas reported sales of around $22 million for Xospata in the first quarter of fiscal 2019, and has said it expects that to increase to around $140m for the full-year.

The post Astellas gets EU approval for AML drug Xospata appeared first on .

from https://pharmaphorum.com/news/astellas-gets-eu-approval-for-aml-drug-xospata/

0 notes

omkeshwari-blog · 5 years

Text

Global Elspar Market Market Outlook, Revenue, Trends and Forecasts Research Report 2019-2025

Global Elspar market: Snapshot Market Overview of Elspar Market : The report provides a global analysis of Elspar Market 2019 Report provides Insightful information to the clients enhancing their basic leadership capacity identified. This Report is segmented into Manufactures, Types, Applications, and Regions. The market covers the wide spectrum of the factors governing future growth including drivers, challenges, emerging trends, technology changes, and environmental factors. Erwinia L-Asparaginase is an enzyme, as a medication it is used to treat acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML), and non-Hodgkin's lymphoma. It is given by injection into a vein, muscle, or under the skin. A pegylated version is also available.The global Elspar market was xx million US$ in 2018 and is expected to xx million US$ by the end of 2025, growing at a CAGR of xx% between 2019 and 2025. The analysis includes market size, upstream situation, market segmentation, market segmentation, price & cost and industry environment. In addition, the report outlines the factors driving industry growth and the description of market channels. The report begins from overview of industrial chain structure, and describes the upstream. Besides, the report analyses market size and forecast in different geographies, type and end-use segment, in addition, the report introduces market competition overview among the major companies and companies profiles, besides, market price and channel features are covered in the report Request for Sample Report @ https://www.acquiremarketresearch.com/sample-request/80693/ The Elspar market report analyses the growth opportunities as well as the threats to the Elspar market w.r.t Business Tactics, Sales Volume and Latest Developments that are taking place in Elspar Industry. Facts such as the Product launch events, Elspar industry news, growth drivers, challenges and investment scope have been analyzed at depth in Elspar research report. Some of the most prominent Key Vendors: Jazz Pharmaceuticals, Shire, Medac GmbH, Kyowa Hakko Kirin, Qianhong Bio-pharma, Taj Pharmaceuticals, Mingxing Pharma, Exova (SL Pharma), United Biotech Regions covered in the market report: North America (United States, Canada and Mexico), Europe (Germany, France, UK, Russia and Italy), Asia-Pacific (China, Japan, Korea, India and Southeast Asia), South America (Brazil, Argentina, Colombia etc.), Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa) Applications Segment Analysis: Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Other Product Segment Analysis: Escherichia coli, Erwinia Chrysanthemi, Pegylated Grab Your Report at an Impressive Discount! Please click here (with Business Email-Id) @https://www.acquiremarketresearch.com/discount-request/80693/ The study objectives of this report are: • To study and forecast the market size of Elspar market. • To analyze the global key players, SWOT analysis, value and global market share for top players. • To define, describe and forecast the market by type, end use and region. • To analyze and compare the market status and forecast between China and major regions, namely, North America, Europe, France, UK, Asia-Pacific, South America and Middle East and Africa. • To analyze the global key regions market potential and advantage, opportunity and challenge, restraints and risks. • To identify significant trends and factors driving or inhibiting the market growth. • To analyze the opportunities in the market for stakeholders by identifying the high growth segments. • To strategically analyze each submarket with respect to individual growth trend and their contribution to the market • To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market • To strategically profile the key players and comprehensively analyze their growth strategies. Browse the full report Description, TOC and Table of Figure @ https://www.acquiremarketresearch.com/industry-reports/elspar-market/80693/ Our experts and analysts evaluate the vendors in the Elspar market and provide understandings to articulate current and future market trends, innovation, customer expectations and competitive forces. The overviews, SWOT analysis and strategies of each vendor in the market provide understanding about the Elspar market forces and how those can be oppressed to create future opportunities.

#Elspar Elspar Market Future Elspar Market Growth Elspar Sales Market News Acquire Market Research

0 notes

healthcare00897 · 5 years

Text

CAR T Cell Therapy Market Is Touching New Levels – To Grow at a healthy CAGR by 2026 with Key players

Coherent Market Insights released a new market study on 2028 CAR T Cell Therapy Market with 100+ market data Tables, Pie Chat, Graphs & Figures spread through Pages and easy to understand detailed analysis. At present, the market is developing its presence.

Download PDF Brochure @ https://www.coherentmarketinsights.com/insight/request-pdf/102

The Research report presents a complete assessment of the Market and contains a future trend, current growth factors, attentive opinions, facts, and industry validated market data. Report offering you more creative solutions that combine our deep geographic experience, intimate sector knowledge and clear insights into how to create value in your business. The research study provides estimates for 2018-2026 CAR T Cell Therapy Market Forecast till 2026.

Synopsis - CAR T Cell Therapy Market Research Report covers insights of CAR T Cell Therapy industry over past five to eight years and forecast until 2018-2026. CAR T Cell Therapy Market report helps to analyse competitive developments such as joint ventures, strategic alliances, mergers and acquisitions, new product developments, and research and developments in the Global CAR T Cell Therapy Market 2018 Industry Trend and Forecast 2026

Market Dynamics:

CAR-T cell therapy is expected to be an important development in cancer treatment and therapeutics industry due to its cost efficiency. Moreover, rising incidence of cancer is leading to high demand for its treatment. According to the World Cancer Research Fund International (WCRFI), around 14.1 million cancer cases were reported worldwide, in 2012. As per WCRFI, it is projected that by 2035, around 24 million cancer cases would be observed worldwide. Moreover, introduction of new therapies into the market is further expected to bolster growth of CAR-T cell therapy market. For instance, in October 2017, the U.S. Food and Drug Administration granted marketing approval to Yescarta (axicabtagene ciloleucel), a cell-based gene therapy, to treat adult patients with certain types of large B-cell lymphoma. However, risks of side effects resulting in various neurological disorders is expected to hinder growth of the global CAR-T cell therapy market.

CAR T Cell Therapy Market report provides key statistics on the Market status of the CAR T Cell Therapy manufacturers and is a valuable source of guidance and direction for companies and individuals interested in the CAR T Cell Therapy industry. The CAR T Cell Therapy Market report also presents the vendor landscape and a corresponding detailed analysis of the major vendors operating in the Market.

Top Key Players of CAR T Cell Therapy Market: Medtronic, Inc. (Covidien), Penumbra, Inc., Stryker Corporation, Johnson & Johnson and Terumo Corporation

Regions of CAR T Cell Therapy Market:

North America: United States, Canada, Mexico

Europe: Germany, France, UK, Russia, Italy, Rest of Europe

Middle East Africa: Turkey, Egypt, South Africa, GCC Countries, Rest of Middle East & Africa

Asia-Pacific: China, India, Australia, Japan, South Korea, Indonesia, Malaysia, Philippines, Thailand, Vietnam

In the end, the report makes some important proposals for a new project of CAR T Cell Therapy Industry before evaluating its feasibility. Overall, the report provides an in-depth insight of global CAR T Cell Therapy industry covering all important parameters.

• CAR T Cell Therapy Driver

• CAR T Cell Therapy Challenge

• CAR T Cell Therapy Trends

Ask For Discount Before Purchasing This Business Report : https://www.coherentmarketinsights.com/insight/request-discount/102

Further, in the CAR T Cell Therapy Market research report, the following points are included along with an in-depth study of each point:

• Production Analysis - Production of the CAR T Cell Therapy is analyzed with respect to different regions, types, and applications. Here, price analysis of various CAR T Cell Therapy Market key players is also covered.

• Sales and Revenue Analysis - Both, sales and revenue are studied for the different regions of the global CAR T Cell Therapy Market. another major aspect, price, which plays an important part in the revenue generation is also assessed in this section for the various regions.

• Supply and Consumption - In continuation with sales, this section studies supply and consumption for the CAR T Cell Therapy Market. This part also sheds light on the gap between supply and consumption. Import and export figures are also given in this part.

• Other analyses - Apart from the information, trade and distribution analysis for the CAR T Cell Therapy Market, contact information of major manufacturers, suppliers and key consumers are also given. Also, SWOT analysis for new projects and feasibility analysis for new investment are included.

• In continuation with this data, the sale price is for various types, applications and region is also included. The CAR T Cell Therapy Market for major regions is given. Additionally, type wise and application wise consumption figures are also given.

Detailed Segmentation:

• Global CAR-T Cell Therapy Market, by Targeted Antigen:

◦ CD 19

◦ BCMA

◦ HER2

◦ GD2

◦ CD 20

◦ CD22

◦ CD30

◦ CD33

◦ HER1

◦ Others

• Global CAR-T Cell Therapy Market, by Therapeutic Application:

◦ Acute Lymphocytic Leukemia

◦ Chronic Lymphocytic Leukemia

◦ Diffuse Large B-cell Lymphoma (DLBCL)

◦ Follicular Lymphoma

◦ Mantle Cell Lymphoma

◦ Multiple Myeloma

◦ Glioblastoma

◦ Sarcoma

◦ Neuroblastoma

◦ Acute Myeloid Leukemia

◦ Breast Cancer

◦ Pancreatic Cancer

◦ Hepatocellular Carcinoma

◦ Colorectal Cancer

◦ Others

• Global CAR-T Cell Therapy Market, by Region:

◦ North America

◦ Europe

◦ Asia Pacific

◦ Latin America

◦ Middle East

◦ Africa

In this study, the years considered to estimate the market size of 2018-2026 CAR T Cell Therapy Market are as follows:

History Year: 2015-2017

Base Year: 2017

Estimated Year: 2018

Forecast Year 2018 to 2026

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Mr. Shah

Coherent Market Insights

1001 4th Ave, #3200

Seattle, WA 98154

Tel: +1-206-701-6702

Email: [email protected]

#CAR T Cell Therapy MarketCAR T Cell Therapy trendsCAR T Cell Therapy growthCAR T Cell Therapy insightsCAR T Cell Therapy outlook

0 notes

myabhijitr · 6 years

Text

Poly Adenosine Diphosphate Ribose Polymerase Market – Size, Growth and Analysis, 2026

Poly adenosine diphosphate ribose polymerase (PARP) is a family of 17 enzymes that combine several (poly) units of ADP-ribose in a chain and transfer them to the target proteins. These proteins aid in restoring the damage in DNA caused due to various factors such as exposure to UV rays, radiation, some anti-cancer drugs or other substances in the environment. PARP inhibitors aid in blocking the enzyme important for the repair of single stranded breaks in DNA that effectively destroys cancer cells. These inhibitors play an effective role in current cancer-combating strategies, owing to its effectiveness in eliminating cancer cells as compared to the existing ovarian cancer treatments. Drugs such as Talazoparib and Veliparib that aid in treatment of ovarian cancer are in phase III clinical trials. Such research and development activities is a key factor contributing to the global poly adenosine diphosphate ribose polymerase market growth.

Request Sample Copy Of This Report: https://www.coherentmarketinsights.com/insight/request-sample/2029

Poly Adenosine Diphosphate Ribose Polymerase Market Drivers

High prevalence of various types of cancer is a key factor contributing to growth of the global poly adenosine diphosphate ribose polymerase market. Cancer is one of the most prevalent fatal chronic disorders with a high mortality rate due to its invasive nature and prolonged duration of disease. According to American Cancer Society (ASC), around 22,240 women are expected to be diagnosed with ovarian cancer, and around 14,070 deaths are expected from the disease in 2018.

Furthermore, introduction of new drugs has propelled the poly adenosine diphosphate ribose polymerase market growth. For instance, the U.S. Food & Drug Administration approved 3 PARP inhibitors—Olaparib, Rucaparib, and Niraparib. These drugs are a potential alternative that aid in treatment of ovarian and other cancers after paclitaxel.

Moreover, combination of these PARP inhibitors with other therapies such as monoclonal antibodies is under research. For instance, in May 2018, TESARO, Inc.—an oncology-focused biopharmaceutical company— announced collaboration with Genentech—a member of the Roche Group—to evaluate the combination of the PD-L1 antibody— Atezolizumab (TECENTRIQ), the MEK inhibitor cobimetinib (COTELLIC), and TESARO’s PARP inhibitor ZEJULA (Niraparib) — in patients with platinum-sensitive ovarian cancer. In April 6, 2018, the U.S. Food and Drug Administration (FDA) approved Rubraca (rucaparib) tablets --manufactured by Clovis Oncology Inc.—for the treatment of recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer in adult patients.

However, various side effects such as possibility of myelodysplastic syndrome or acute myeloid leukemia due to Lynparza (Olaparib), resistance to PARP inhibitors, and regulatory challenges are some of the factors that are expected to hamper the poly adenosine diphosphate ribose polymerase market growth.

Download PDF Brochure @ https://www.coherentmarketinsights.com/insight/request-pdf/2029

Poly Adenosine Diphosphate Ribose Polymerase Market Regional Insights

North America and Europe are expected to witness significant growth in the poly adenosine diphosphate ribose polymerase market over the forecast period. Increasing demand for approved drugs, owing to high prevalence of various types of cancer is expected to facilitate growth of the market, in the U.S. For instance, according to American Cancer Society (ASC), around 164,690 new cases are expected to be diagnosed with prostate cancer in 2018.

New product launches and robust pipeline of PARP inhibitors is expected to boost the North America, and Europe PARP inhibitors market growth over the forecast period. For instance, Clovis Oncology launched Rubraca (Rucaparib) in 2016, and Tesaro, Inc. launched Zejula (Niraparib) in 2017. Moreover, Lynparza (Olaparib) manufactured by AstraZeneca Plc was approved by the U.S. Food & Drug Administration for the treatment of germline BRCA-mutated (gBRCAm), human epidermal growth factor receptor 2 (HER2)-negative metastatic breast cancer in January 2018.

Poly Adenosine Diphosphate Ribose Polymerase Market Key Player

Key players operating in the poly adenosine diphosphate ribose polymerase market include Tesaro Inc., Clovis Oncology, AstraZeneca, Pfizer, Inc., and AbbVie Inc.

Poly Adenosine Diphosphate Ribose Polymerase Market Taxonomy

The global poly adenosine diphosphate ribose polymerase market is segmented on the basis of drug, cancer type, distribution channel, and region. By Drug – Olaparib, Rucaparib, Niraparib, Others,. By Cancer Type - Prostate Cancer, Ovarian Cancer, Others,. By Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Online Pharmacies,. By Region - North America, Europe, Asia Pacific, Latin America, Middle East, Africa,.

Click To Continue Reading On Poly Adenosine Diphosphate Ribose Polymerase Market

About Coherent Market Insights:

Mr. Shah Coherent Market Insights 1001 4th Ave, #3200 Seattle, WA 98154 Tel: +1-206-701-6702 Email: [email protected]

Visit our news Website: https://www.coherenttimes.org

#Poly Adenosine Diphosphate Ribose Polymerase Market Research #Poly Adenosine Diphosphate Ribose Polymerase Market

0 notes